Investigational Drug Information for ANAVEX2-73
✉ Email this page to a colleague
What is the drug development status for ANAVEX2-73?
ANAVEX2-73 is an investigational drug.
There have been 9 clinical trials for ANAVEX2-73.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 3rd 2018.
The most common disease conditions in clinical trials are Alzheimer Disease, Syndrome, and Rett Syndrome. The leading clinical trial sponsors are Anavex Life Sciences Corp., Anavex Germany GmbH, and Anavex Australia Pty Ltd.
There are two US patents protecting this investigational drug and forty-eight international patents.
Summary for ANAVEX2-73
| US Patents | 2 |
| International Patents | 48 |
| US Patent Applications | 62 |
| WIPO Patent Applications | 21 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2018-07-03) |
| Vendors | 51 |
Recent Clinical Trials for ANAVEX2-73
| Title | Sponsor | Phase |
|---|---|---|
| ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | Anavex Australia Pty Ltd. | Phase 2/Phase 3 |
| ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | Anavex Germany GmbH | Phase 2/Phase 3 |
| ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | Anavex Life Sciences Corp. | Phase 2/Phase 3 |
Clinical Trial Summary for ANAVEX2-73
Top disease conditions for ANAVEX2-73
Top clinical trial sponsors for ANAVEX2-73
US Patents for ANAVEX2-73
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ANAVEX2-73 | ⤷ Sign Up | Use of Sigma-1 receptor agonist compounds | MTA Tamogatott Kutatocsoportok Irodaja (Budapest, HU) Semmelweis Egyetem (Budapest, HU) | ⤷ Sign Up |
| ANAVEX2-73 | ⤷ Sign Up | Combination of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide and a NMDA receptor antagonist and pharmaceutical compositions containing the same | Les Laboratoires Servier (Suresnes Cedex, FR) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ANAVEX2-73
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ANAVEX2-73 | Canada | CA2938928 | 2034-02-07 | ⤷ Sign Up |
| ANAVEX2-73 | China | CN106456578 | 2034-02-07 | ⤷ Sign Up |
| ANAVEX2-73 | Denmark | DK3104847 | 2034-02-07 | ⤷ Sign Up |
| ANAVEX2-73 | European Patent Office | EP3104847 | 2034-02-07 | ⤷ Sign Up |
| ANAVEX2-73 | Spain | ES2848710 | 2034-02-07 | ⤷ Sign Up |
| ANAVEX2-73 | Croatia | HRP20210114 | 2034-02-07 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
